Most Read

The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials in castration-resistant prostate cancer (CRPC). Detailed results will

The new facility, which is strategically located in close vicinity to the Ljubljana Airport, will carry out the distribution of finished products worldwide and will be used for

Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent

Under the terms of the agreement, Innovare will use DelSiTech’s technology on its peptide membrane fusion inhibitor, targeting the envelope protein of human immunodeficiency virus-1 (HIV-1). DelSiTech is

MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via

The trial was held in patients who previously experienced inadequate responses to two to four classes of preventive treatments. In the study of 838 patients, including those who

Alvotech and Fuji Pharma recently announced an exclusive agreement for development and commercialization of biosimilars in Japan. Fuji´s investment into Alvotech further strengthens the partnership between the companies

Zirabev is a monoclonal antibody for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer

The product candidates include pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor). Under the terms of the agreement, Innovent will pay Incyte US$40m in cash up